Oral peptides and protein-based therapeutics have been in use for more than three decades since the approval of recombinant human insulin, the first protein therapy, in 1982. Earlier, most biologic drugs were the subcutaneous biologics. However, over time, advances in delivery formulations have enabled the development of oral peptides / proteins. Owing to numerous compelling reasons, the concept of peptide pills has gained significant traction. The need for efficient and patient-friendly treatment options for chronic disorders, such as diabetes, is estimated to boost the demand for oral proteins and peptides in the coming years.
Robust Development Pipeline
With two approved drugs and close to 100 clinical / preclinical product candidates, the field of oral protein / peptides therapeutics has evolved significantly over time.
Widening Influence Across Multiple Therapeutic Areas
Majority of product candidates are in early developmental phases, targeting a wide range of disease indications based on novel technologies
Novel Technology Platforms: A Vital Enabler
Ongoing advancements have led to the development of innovative technology platforms, which are designed to improve oral delivery and bioavailability of biologics.
US, EU: The Innovation Hubs
Driven by the efforts of small to mid-sized companies, as well as established players, current research activity is heavily concentrated in the US and certain parts of Europe.
Growing KOL Community
In fact, several prominent scientists, acting as key opinion leaders, have made significant contributions to clinical development efforts.
Insights from Social Media
Increasing chatter on social media, and the fact that multiple scientific articles have been published in the last few years, are indicative of the growing interest in this domain.
VC Funding: A Key Driver
Consequently, companies engaged in the oral proteins and oral peptides market have raised close to USD 5.4 billion in financing, as investors have grown to realize the numerous benefits and future potential of oral therapies
A Multi-Billion Dollar Opportunity
Prevalent trends indicate that the market is poised to grow at a significant pace in the mid to long term as late stage molecules get commercialized in the future.
Well-Distributed and Relatively Low-Risk Growth
The opportunity is anticipated to be well-distributed across multiple technology platforms and different geographical regions
To learn more, please click here. For any queries / suggestions, please do not hesitate to contact us at firstname.lastname@example.org. You can also download the SAMPLE REPORT on oral peptides by Roots Analysis.
For further information on this domain, check our report here.
Arun is an enthusiastic professional and has been associated with Roots Analysis since the very early years. He has led multifaceted roles over the years be it business research, consulting, competitive intelligence, IT & technology, sales and marketing. He currently drives strategic thinking and execution within the sales and marketing domain. With educational background in life sciences from Thapar University and digital marketing credentials from Indian School of Business, he has led a lot of critical initiatives at the organization. His background in life sciences has been one of the key reasons for quick understanding and implementation of customized marketing strategies. During his early years, he has led multiple consulting assignments for global clients ranging from competitive landscaping, deal structuring and preparing go-to-market strategy for his clients.